<PAGE> 1
OMB APPROVAL
OMB NUMBER: 3235-0145
UNITED STATES Expires: October 31, 1994
SECURITIES AND EXCHANGE COMMISSION Estimated average burden
Washington, D.C. 20549 hours per form ....... 14.90
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 6)*
-
BIOCHEM INTERNATIONAL INC.
- -------------------------------------------------------------------------------
(Name of Issuer)
Common Stock ($0.02 par value)
- -------------------------------------------------------------------------------
(Title of Class Securities)
090585 10 0
-------------------------------
(CUSIP Number)
Stephen Marcus, Holleb & Coff, 55 E. Monroe St., Ste. 4100, Chicago, IL 60603
(312) 807-4600
- -------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive Notices
and Communications)
March 2, 1998
--------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box / /.
Check the following box if a fee is being paid with the statement / /. (A
fee is not required only if the report person: (1) has a previous statement on
file reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less or such class.)
(See Rule 13d-7)
Note: Six copies of this statement, including all exhibits, should be filed
with the Commission. See Rule 13d-1(a) for other parties to whom copies are to
be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
disclosures provided in prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
<PAGE> 2
CUSIP NO. 090585 10 0 Page 2 of 9 pages
----------------------- ---- ----
<TABLE>
<S><C>
- ------------------------------------------------------------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S OR I.R.S IDENTIFICATION NO. OF ABOVE PERSON
DS MEDICAL PRODUCTS CO.
- ------------------------------------------------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / /
(b)/ /
- ------------------------------------------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- ------------------------------------------------------------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
N/A
- ------------------------------------------------------------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) / /
- ------------------------------------------------------------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
State of Illinois
- ------------------------------------------------------------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES --------------------------------------------------------------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 0
EACH --------------------------------------------------------------------------------------------------------------------
REPORTING 9 SOLE DISPOSITIVE POWER
PERSON 0
WITH --------------------------------------------------------------------------------------------------------------------
10 SHARE DISPOSITIVE POWER
0
- ------------------------------------------------------------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0
- ------------------------------------------------------------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / /
- ------------------------------------------------------------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
--
- ------------------------------------------------------------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO.
- ------------------------------------------------------------------------------------------------------------------------------------
</TABLE>
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
<PAGE> 3
CUSIP NO. 090585 10 0 Page 3 of 9 pages
----------------------- ---- ----
<TABLE>
<S><C>
- ------------------------------------------------------------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S OR I.R.S IDENTIFICATION NO. OF ABOVE PERSON
KEN M. DAVEE
- ------------------------------------------------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / /
(b)/ /
- ------------------------------------------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- ------------------------------------------------------------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
N/A
- ------------------------------------------------------------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) / /
- ------------------------------------------------------------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
U.S.
- ------------------------------------------------------------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 4,992,500
SHARES --------------------------------------------------------------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 0
EACH --------------------------------------------------------------------------------------------------------------------
REPORTING 9 SOLE DISPOSITIVE POWER
PERSON 4,992,500
WITH --------------------------------------------------------------------------------------------------------------------
10 SHARE DISPOSITIVE POWER
0
- ------------------------------------------------------------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,992,500
- ------------------------------------------------------------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / /
- ------------------------------------------------------------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
37.79%
- ------------------------------------------------------------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
- ------------------------------------------------------------------------------------------------------------------------------------
</TABLE>
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
<PAGE> 4
CUSIP NO. 090585 10 0 Page 4 of 9 pages
----------------------- ---- ----
<TABLE>
<S><C>
- ------------------------------------------------------------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S OR I.R.S IDENTIFICATION NO. OF ABOVE PERSON
DAVID H. SANDERS
- ------------------------------------------------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / /
(b)/ /
- ------------------------------------------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- ------------------------------------------------------------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
N/A
- ------------------------------------------------------------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) / /
- ------------------------------------------------------------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
U.S.
- ------------------------------------------------------------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 4,636,566
SHARES --------------------------------------------------------------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 0
EACH --------------------------------------------------------------------------------------------------------------------
REPORTING 9 SOLE DISPOSITIVE POWER
PERSON 4,636,566
WITH --------------------------------------------------------------------------------------------------------------------
10 SHARE DISPOSITIVE POWER
0
- ------------------------------------------------------------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,636,566
- ------------------------------------------------------------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / /
- ------------------------------------------------------------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
35.09%
- ------------------------------------------------------------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
- ------------------------------------------------------------------------------------------------------------------------------------
</TABLE>
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
<PAGE> 5
Page 5 of 9 pages
--- ---
SCHEDULE 13D
(AMENDMENT NO. 6)
ITEM 1. SECURITY AND ISSUER.
Title and Class of Securities: Common stock, $.02 par value.
Name and Address of Principal Executive Offices of the Issuer:
Biochem International Inc. (referred to herein as "Biochem"), W238
N1650 Rockwood Drive, Waukesha, Wisconsin 53188-1199.
ITEM 2. IDENTITY AND BACKGROUND.
Person Filing:
(a-1) Name: DS Medical Products Co. (referred to herein as
"DS Medical")
(b-1) State of Incorporation: Illinois
(c-1) Principal Business: The design, development, manufacture
and sale of medical products and investment in the
securities of one or more companies engaging in such
activities. Address of Principal Business and Principal
Office: c/o Ken M. Davee, 180 East Pearson Street,
Chicago, Illinois 60611.
(d-1) DS Medical has not, during the last five years, been
convicted in a criminal proceeding.
(e-1) DS Medical was not, during the last five years, a party
to any civil proceeding as a result of which it was or is
subject to a judgment, decree or final order enjoining
future violations of, or prohibiting or mandating
activities subject to, federal or state securities laws
or finding any violation with respect to such laws.
(f-1) Citizenship: Not applicable.
Executive Officers, Directors and Controlling Persons of DS Medical.
[THIS SCHEDULE 13D IS FILED ON BEHALF OF THE FOLLOWING INDIVIDUALS,
AS WELL, PURSUANT TO RULE 13D-1(F)]
<PAGE> 6
Page 6 of 9 pages
--- ---
(a-2) Names: Ken M. Davee and David H. Sanders.
(b-2) Business Addresses: The business address for Mr. Davee
is 180 East Pearson Street, Chicago, Illinois 60611, and
for Mr. Sanders is Biochem International Inc., W238
N1650 Rockwood Drive, Waukesha, Wisconsin 53188-1199.
(c-2) Present Principal Occupations:
Name Principal Occupation
---- --------------------
Ken M. Davee President, Secretary and director of DS
Medical, Secretary and a director of
Biochem International Inc., and a private
investor
David H. Sanders Chairman, Chief Executive Officer,
Treasurer, and director of Biochem
International Inc., and Treasurer and
director of DS Medical
(d-2) No executive officer, director or controlling person of
DS Medical listed above has, during the last five years,
been convicted in a criminal proceeding.
(e-2) No executive officer, director or controlling person of
DS Medical listed above was, during the last five years,
a party to any civil proceeding as a result of which he
was or is subject to a judgment, decree or final order
enjoining future violations of, or prohibiting or
mandating activities subject to, federal or state
securities laws or finding any violation with respect to
such laws.
(f-2) Citizenship: The executive officers, directors and
controlling persons of DS Medical listed above are
citizens of the United States of America.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
The shares that are the subject of this Schedule 13D were acquired
by reason of the merger of DS Medical with and into Biochem,
effective March 2, 1998, and the related surrender, for cancellation
and exchange, of the shares of DS Medical previously held by the
reporting persons.
<PAGE> 7
Page 7 of 9 pages
--- ---
ITEM 4. PURPOSE OF TRANSACTION.
DS Medical was the investment vehicle through which Ken M. Davee and
David H. Sanders owned a controlling interest in the stock, and
controlled the business, of Biochem.
The purpose of the merger of DS Medical with and into Biochem was to
provide a tax-efficient method by which to distribute the shares of
Biochem previously held by DS Medical to direct record ownership by
the former shareholders of DS Medical.
While the reporting persons are not presently engaged in any
negotiations or discussions with any parties proposing an
acquisition of Biochem or its business or assets, the reporting
persons, as management and the principal beneficial stockholders of
Biochem, have, from time to time, been approached by parties
proposing such an acquisition (see Biochem Reports on Form 8-K,
dated May 23, 1995 and July 25, 1995), and the reporting persons, in
such capacities, reserve the right to solicit, initiate, entertain,
consider, discuss and negotiate offers for the sale or other
transfer of the stock or assets of Biochem from time to time.
The ownership of a significant majority of the outstanding capital
stock of Biochem by the reporting persons and related parties means
that any such discussions, negotiations and transfer could be
accomplished when, as and on terms, deemed advantageous to those
principal shareholders, which may not coincide with the interests or
anticipated timing of minority shareholders.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
DS Medical was the record and beneficial owner of 9,985,000 shares
of Biochem common stock, representing 76.52% of the number of shares
of the class outstanding.
The separate existence of DS Medical ceased as a result of the
merger of DS Medical with and into Biochem, effective March 2, 1998.
Accordingly, DS Medical will no longer be a reporting person
hereunder.
As a result of the merger, Ken M. Davee became the direct beneficial
owner of 4,992,500 shares of the common stock of Biochem,
representing 38.26% of the number of shares of Biochem common stock
outstanding.
<PAGE> 8
Page 8 of 9 pages
--- ---
As a result of the merger, David H. Sanders became the direct
beneficial owner of 4,636,566 shares of the common stock of Biochem,
representing 35.53% of the number of shares of Biochem common stock
outstanding.
(Messrs. Davee and Sanders each own the shares of Biochem received
by them in the merger as trustee of a revocable trust for their
respective individual benefit.)
For all purposes hereunder, the percent of class calculation is
based on a total of 13,049,284 shares issued and outstanding.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH
RESPECT TO SECURITIES OF THE ISSUER.
Messrs. Davee and Sanders have been co-investors in Biochem since
1984, using DS Medical as their ownership vehicle. Throughout that
time, they were substantially equal owners of the stock of DS
Medical and their joint acquiescence was a practical requirement for
action by DS Medical. As a result of the termination of the
separate existence of DS Medical, each of Messrs. Davee and Sanders
are free to deal with their respective shares of Biochem as they may
individually determine. However, in light of their historical
business relationship, and the relatively large percentage of
Biochem of which each remains the owner, it is expected that any
material transaction involving Biochem would be accomplished with
the joint agreement of Messrs. Davee and Sanders.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.
The parties' signatures hereto evidence their agreement that this
statement is filed on behalf of each of them as required by Rule
13d-1(f).
SIGNATURE
After reasonable inquiry and to the best of our knowledge and belief,
each of the undersigned certify that the information set forth in this
statement is true, complete and correct.
<PAGE> 9
Page 9 of 9 pages
--- ---
Each of the undersigned hereby agrees that this statement is filed on
behalf of each of them pursuant to Rule 13d-1(f).
Dated: March 31, 1998 DS MEDICAL PRODUCTS CO.
By: s/Ken M. Davee
----------------------------
Ken M. Davee, President
s/Ken M. Davee
-------------------------------
Ken M. Davee
s/David H. Sanders
-------------------------------
David H. Sanders
